Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells
| Autor: | Ju Qiao, Tianli Shen, Qian Xiao, Zhengxi Chen, Xuejun Sun |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Cancer Research Colorectal cancer medicine.drug_class Adenomatous polyposis coli medicine.medical_treatment Immunology Monoclonal antibody medicine.disease_cause lcsh:RC254-282 Targeted therapy 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine medicine lcsh:QH573-671 Lung cancer biology business.industry lcsh:Cytology Cancer Cell Biology medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3. Good health 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Cancer research KRAS Antibody business |
| Zdroj: | Cell Death Discovery, Vol 5, Iss 1, Pp 1-12 (2019) |
| ISSN: | 2058-7716 |
| Popis: | Adenomatous polyposis coli (APC) and KRAS proto-oncogene (KRAS) mutations frequently co-occur in non-small cell lung cancer. Inactivating APC mutations in colorectal carcinoma has been well characterized, leading to the approaches targeting on dysregulated APC pathway. However, it remains undetermined whether such approaches are also applicable to non-small cell lung cancer patients harboring similar mutations of APC. Dickkopf-related protein 2 (DKK2) is a Wnt antagonist. Our previous study has proved that anti-DKK2 antibody 5F8 suppressed the growth of colorectal carcinoma with APC mutations, illustrating a new target agent of APC-mutated tumors. This study aimed to investigate the potential of applying anti-DKK2 antibody to non-small cell lung cancer with APC mutations. We found significant upregulation of Dkk2 expression in APC-mutated lung cancers. Administration of DKK2 antibody inhibited cancer growth via modulating tumor immune microenvironment in lung cancer mouse models. Our study provided strong evidence supporting APC mutations-directed applications of anti-DKK2 targeted therapy in a wide range of cancer types, including lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|